Post-Doctoral Fellowship in Oncology/Clinical Pharmacology
The Duke Division of Hematology’s advanced fellowship is designed to prepare physicians for a career in pharmaceutical research and development, academia, clinical research, or with a governmental agency that deals with drugs or therapeutics.
The program takes advantage of the combined expertise of Duke, one of 14 NCI-designated phase I centers of excellence, and GlaxoSmithKline (GSK), one of the world's leading pharmaceutical companies.
Focus is on the design and conduct of innovative clinical trials with novel anti-cancer agents. This program will emphasize phase I studies that will incorporate pharmacology, imaging, and other biomarker/pharmacodynamic assessments.
Program Training Director: Herbert Hurwitz, MD
Duration: Two years
Start date: July 1
Prerequisite: Successful completion of two years of training in Duke’s Hematology/Oncology Fellowship Program
Oncology/Clinical Pharmacology fellows will:
- Develop a complete clinical drug research proposal, from conception and design to approval, which embodies the clinical and scientific principles basic to clinical research and drug development
- Participate in the conduct of clinical drug trials that would result in publications in peer-reviewed professional journals and/or in reports suitable for submission for action by a regulatory agency
- Apply appropriate ethical, legal, and regulatory issues to research involving investigational and marketed drugs
- Gain experience as a clinical researcher in the academic, clinical, and pharmaceutical fields
Fellows will spend time at the Duke Cancer Institute at Duke University and GlaxoSmithKline located in Research Triangle Park, approximately 20 minutes from Duke.
For additional information or to apply, contact:
Herbert Hurwitz, MD
Clinical Director, Phase I Program
Duke Cancer Institute
Box 3052, Room 25132 Morris Bldg
Duke University Medical Center
Durham, NC 27710